Israeli company Kadimastem is developing regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as Amyotrophic lateral sclerosis (ALS) and diabetes. Catherine Longworth spoke with Kadimastems head of diabetes research, Kfir Molakandov to find out more.
In the 1990s, when the first transplant of islets took place, it was hailed as the cure for diabetes. But years later, the potential of islet therapy is yet to be realised due to difficulties finding donors and harvesting cells.
Only a few thousand people have benefited from this therapy as there are not enough donors, says Kfir Molakandov. But even if there were enough donor islets, the standardisation of this therapy is horrible. Every donor is different, and if you offer a therapy, it should be good, reliable, consistent, and the same for everyone.
As the head of diabetes research at Israeli cell therapy company Kadimastem, Molakandov believes they could have the next major diabetes therapy. The Tel-Aviv listed company is leading research and development of a cell therapy comprising functional pancreatic islet cells.
The product in development, IsletRx, is clinical grade pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels. Using micro-encapsulation technology, integrated within IsletRx, the islet cells are protected from attack by the host immune system.
Diabetes is a very hard disease to manage, especially with young children. You have to calculate everything from how much you eat, the amount of insulin to inject, and how much physical exercise to take everything has to be managed! With our therapy, we aim to make it easy by simply putting the functional cells in the patient, Molakandov tells pharmaphorum.
Founded in 2009 by Kadimastems chief scientist Professor Michel Revel, the therapy is based on stem cell research from Israels Weizmann Institute of Science, looking at the potential of restoring activity lost in tissues due to disease damage. After developing treatments for multiple sclerosis, he turned his focus to two main disease areas diabetes and ALS.
Any tissue in the body can be made from the stem cells as they are immature, very easy to work with cells and can proliferate as much as we want to become whatever we want, says Molakandov. We see the cells like clay in our hands that we manipulate in culture and mimic development processes. We have ways to maneuver stem cells to the destination and target tissue we want. We just accelerate the process that takes place in utero over nine months and follow the same stages in a shorter time period.
Kadimastems lead product for ALS, AstroRx, is a cell therapy product containing astrocytes derived from human embryonic stem cells. The astrocyte cells are injected directly into the cerebrospinal cord fluid of the patients to support the dying motor neurons in the brain and spinal cord of ALS patients and slow progression of the disease.
In March 2021, the company completed a Phase 1/2a clinical trial at Jerusalems Hadassah Medical Center, which validated safety and efficacy. The study results show a high safety profile of AstroRx cells and also demonstrated that this particular approach significantly decreased the progression of the disease for three months after AstroRx administration, when measured by ALS Functional Rating Scale-Revised (ALSFRS-S). The company aims to test multiple injections of AstroRx cells in the next round of clinical trials to try to prolong the beneficial effect.
We want to lead a diabetes revolution
Seeking approval
For IsletRx, Kadimastem is working with global regulatory authorities to start pre-clinical studies this year. In April 2021, the company announced it had secured $6.8 million in financing to expedite its research and development programmes.
We anticipate that in about two years our diabetes product will be in clinical trials, says Molakandov. In diabetes, we have managed to demonstrate that we have the capability to manufacture the islets in a good, reproducible way and our proof-of-concept studies show that our cells are capable of ameliorating glycaemia in diabetic animals. In mice, we were able to show the dose escalating needed in order to achieve normal glycaemia, so we know most of the things that we need to know about these cells.
Kadimastem is also developing technology to purify non-relevant cells from the production procedure by selecting the right cells to put in the patient. In fact, Kadimastem is the only cell therapy company with this capability.
It is not a process where you get everything you want you sometimes get impurities, so we have a method and patent to take the right cells and put them in the patient.
For years there was no good external marker, something the cell expresses on its surface, that correlates with the phenotype of mature beta cell. We did a collaboration with scientists at the Weizmann Institute, and we actually managed to identify a single marker that correlates to what is called mature function, so we are using this marker to clear the culture and only use targeted function in the cells that we want.
Although Kadimastem is currently focusing on type 1 and type 2 diabetes, in the future, Molakandov hopes treatment could be available to pre-diabetic people to halt progression of the disease.
Even if you are treated with insulin and you are balanced, the body still may have experienced damage. Not many companies are doing what we do, so we understand the implications and responsibility.
The COVID-19 pandemic has also put diabetes treatment in the spotlight due to people with diabetes being more likely to have serious complications fromthe virus. Clinical observations have also indicated that the condition may be a consequence of the disease.
We want to lead a diabetes revolution, reflects Molakandov. Personally, I think our work now is like the dream of biologists as it combines many disciplines tissue engineering, biomaterials, development, and large-scale production. We feel really proud to understand and execute all these functions simultaneously.
About the interviewee
Kfir Molakandov is head of diabetes research & bioproduction specialist at Kadimastem. His academic and research career have revolved around stem cell research and therapy in diabetes.
See more here:
Tackling diabetes & ALS with cell therapy - - pharmaphorum
- Shinobi strikes deal with electronics powerhouse Panasonic to create new cell therapy manufacturing platform - FiercePharma - April 19th, 2024
- The Stem Cells Market expected to grow at the value of USD 28.1 Billion by 2030 with a 10.48% CAGR. - WhaTech - April 19th, 2024
- Scientists produce in vitro model of cell differentiation during early facial development - Phys.org - April 19th, 2024
- Somite: AI-Based Stem Cell Therapy Company Closes $5.3 Million In Funding - Pulse 2.0 - April 19th, 2024
- Paralyzed man who can walk again shows potential benefit of stem cell therapy - ABC News - April 5th, 2024
- Stem Cells Market Innovations Investigated by Industry Overview and Global Forecast - WhaTech - April 5th, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - University of Wisconsin-Madison - April 1st, 2024
- The PTM profiling of CTCF reveals the regulation of 3D chromatin structure by O-GlcNAcylation - Nature.com - April 1st, 2024
- Signatures of Autofluorescence Used To Study Stem Cells Aging in the Brain - Technology Networks - March 30th, 2024
- Two decades of embryonic stem cells: a historical overview - March 28th, 2024
- Researchers at Phoenix Children's First in the World to Produce Mouse Lungs in Rats - The Malaysian Reserve - March 26th, 2024
- Unlocking the mysteries of early human development through blastoid models - News-Medical.Net - March 24th, 2024
- Unlocking the Secrets of Aging: Researchers Reveal Key to Intestinal Balance - SciTechDaily - March 17th, 2024
- Human stem-cell-based therapy for Parkinson's disease proven safe PET - BioNews - March 13th, 2024
- Exploring the inner workings of stem cells: When location changes the message - Phys.org - March 9th, 2024
- Confronting IVF: Human Embryos Are Persons With a Right to Life - Walter Bradley Center for Natural and Artificial Intelligence - March 7th, 2024
- When Location Changes the Message - UConn Today - University of Connecticut - March 7th, 2024
- Distinct pathways drive anterior hypoblast specification in the implanting human embryo - Nature.com - March 6th, 2024
- In light of the Alabama court ruling, a look at the science of IVF : Short Wave - NPR - March 3rd, 2024
- The weird way Alabamas embryo ruling takes on artificial wombs - MIT Technology Review - February 25th, 2024
- Alabama's biggest hospital to suspend transfer of embryos after court ruling - ABC News - February 24th, 2024
- Stem Cells: FAQs Answered for Patients and Caregivers - Corporate Wellness Magazine - February 22nd, 2024
- Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells - Business Wire - February 22nd, 2024
- Breakthrough Stem Cell Treatments for Stroke Recovery: What You Need to Know - Medical Tourism Magazine - February 20th, 2024
- Global Cell Isolation Market Size To Worth USD 13.4 Billion By 2033 | CAGR of 12.5% - Yahoo Finance - February 20th, 2024
- The Mechanism of Positional Cues in Embryonic Development and Signaling Molecules in Cell Fate - Medriva - February 18th, 2024
- Regeneration of the Retina Using Pluripotent Stem Cells: A Comprehensive Review - Cureus - February 5th, 2024
- CRISPR/Cas9-mediated deletion of a GA-repeat in human GPM6B leads to disruption of neural cell differentiation from ... - Nature.com - January 29th, 2024
- Global Human Embryonic Stem Cell Market Analysis 2024-2034: A Deep Dive into Applications, End-users, and ... - GlobeNewswire - January 26th, 2024
- No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - Yahoo News - January 14th, 2024
- Clinical applications of stem cell-derived exosomes | Signal Transduction and Targeted Therapy - Nature.com - January 12th, 2024
- How Stem Cell Embryo Models Won Method of the Year - Technology Networks - January 12th, 2024
- Changing the public perception of human embryology - ESHRE - January 11th, 2024
- How the Human Body Regenerates New Cells Every Year - Laughing Squid - January 4th, 2024
- Lab-grown models of embryos increasingly resemble the real thing | Mint - Mint - January 4th, 2024
- Singapore should ban reproductive applications of synthetic human embryos - BioEdge - January 4th, 2024
- Machine learning-based estimation of spatial gene expression pattern during ESC-derived retinal organoid ... - Nature.com - December 21st, 2023
- The development of embryos may be less shaped by genes than we thought - New Scientist - December 21st, 2023
- Embryonic stem cell - Wikipedia - December 13th, 2023
- Researchers discover a mechanism that controls the identity of stem cells - Phys.org - December 9th, 2023
- 'Fascinating and completely unexpected': Tiny robots fix neurons - FierceBiotech - December 5th, 2023
- Establishment and characterization of matched immortalized human ... - Nature.com - December 5th, 2023
- Proteomic insights into the associations between obesity, lifestyle ... - BMC Medicine - December 5th, 2023
- New therapy can treat rare and hereditary diseases - ScienceNorway - December 5th, 2023
- Scientists Still Can't Be Trusted on Gene Editing - Progressive.org - December 5th, 2023
- Harvard Apparatus Regenerative Technology and Renowned ... - Yahoo Finance - December 5th, 2023
- 4.4 Million Funding Injection Fuels World-Class Bioscience Research Programme - India Education Diary - December 3rd, 2023
- A two-kinesin mechanism controls neurogenesis in the developing ... - Nature.com - December 3rd, 2023
- What happens when nature and cities collide - CNN - December 3rd, 2023
- Pro-Life This Week: December 1, 2023 | ALL - All.org - December 3rd, 2023
- A look at the international race to create human eggs and sperm in ... - NPR - December 1st, 2023
- Synthetic genetic circuits to uncover the OCT4 trajectories of ... - Science - December 1st, 2023
- Why the Novo Nordisk Foundation is betting big on stem cells - pharmaphorum - November 29th, 2023
- Charity Watchlist Helps Donors Ensure Their Year-End Gifts Don't ... - All.org - November 29th, 2023
- A green glowing monkey has been created in China. What were the ... - Genetic Literacy Project - November 29th, 2023
- Fetal Bovine Serum Market to reach USD 1.26 Bn by 2029, emerging at a CAGR of 5.3 percent according to a ne... - WhaTech Technology and Markets News - November 29th, 2023
- Implications of Gene Therapy in Dentistry and Periodontics: A ... - Cureus - November 27th, 2023
- Study shows how to treat hereditary, rare diseases - ETHealthWorld - November 27th, 2023
- Drugs identified that may reverse brain fog caused by COVID-19 - New Atlas - November 27th, 2023
- The genes that made us truly human may also make us ill - BBC.com - November 25th, 2023
- Therapy to treat rare, hereditary diseases: Study - Hindustan Times - November 25th, 2023
- How the growth of a giant single cell is intertwined with daily self-rhythms - Phys.org - November 25th, 2023
- On this day: Mahmoud Abbas becomes leader of Fatah in 2004 - In-Cyprus - November 25th, 2023
- Evaluation of A-ring hydroxymethylene-amino- triterpenoids as ... - Nature.com - November 25th, 2023
- Disruption of the autism gene and chromatin regulator KDM5A alters ... - Science - November 23rd, 2023
- Scientists Created a Monkey With Two Different Sets of DNA - Smithsonian Magazine - November 23rd, 2023
- Genomic tug of war could boost cancer therapy - Science Daily - November 23rd, 2023
- What are stem cells? Throw light on various types of stem cells and ... - Insights IAS - November 23rd, 2023
- The Paul G. Allen Family Foundation awards $10.5 million to new ... - EurekAlert - November 23rd, 2023
- Daily briefing: Why these PhD scientists went into teaching - Nature.com - November 23rd, 2023
- Innovative Therapy Targets Rare, Hereditary Diseases - Mirage News - November 23rd, 2023
- Scientists uncover "genomic tug of war" that influences ... - News-Medical.Net - November 21st, 2023
- DOT1L is a barrier to histone acetylation during reprogramming to ... - Science - November 21st, 2023
- Tumor microenvironment composition & related therapy in HCC | JHC - Dove Medical Press - November 21st, 2023
- T-Therapeutics raises $59M in series A for T-cell receptors - BioWorld Online - November 19th, 2023
- A $3bn bet on finding the fountain of youth | Mint - Mint - November 19th, 2023
- A better way to study Parkinson's disease in the lab could lead to ... - EurekAlert - November 17th, 2023
- Global Stem Cell Therapy Market to Reach USD 928.6 Million by ... - GlobeNewswire - November 17th, 2023
- MKL/SRF and Bcl6 mutual transcriptional repression safeguards the ... - Science - November 17th, 2023
- METTL1-Related Genes and Immune Characteristics in SLE | JIR - Dove Medical Press - November 17th, 2023
Recent Comments